Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: $LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longboard Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longboard Pharmaceuticals's position in the market.
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) has announced a proposed underwritten public offering to issue and sell $150 million of shares of its voting common stock, with a 30-day option to purchase up to an additional approximately $22.5 million of shares. Cantor and Citigroup are acting as joint lead book-running managers for the offering, with Wedbush PacGrow and H.C. Wainwright & Co. as lead managers. The offering is being made pursuant to two shelf registration statements on Form S-3, declared effective on October 11, 2022 and August 11, 2023. A preliminary prospectus supplement will be filed with the SEC and will be available for free on the SEC’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.76%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The study showed a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population, with favorable safety and tolerability results. Longboard is rapidly moving forward with preparations for its global Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
316.25%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) to Host Conference Call and Webcast to Discuss Topline Data from PACIFIC Study on Bexicaserin (LP352) for Developmental and Epileptic Encephalopathies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
316.25%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: LBPH), initiated a Phase 1 clinical study for LP659, a potential treatment for rare neuroinflammatory conditions. LP659 is an oral, next-generation sphingosine-1-phosphate (S1P) receptor modulator. The company plans to share Phase 1 SAD data and additional clinical plans for LP659 in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) to Present New Data for LP352 at 2023 AES Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) has announced the grant of inducement awards to a new employee. The Compensation Committee approved the grant of non-qualified stock options to purchase 58,520 shares of common stock at an exercise price of $5.415 per share. The stock options will vest over time based on the employee's start date and continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. completes enrollment for the LP352 Phase 1b/2a PACIFIC Study in August 2023. Topline data for the study is expected in January 2024. The company also plans to initiate the LP659 Phase 1 single-ascending dose (SAD) study in Q4 2023, with topline data expected in the first half of 2024. Longboard Pharmaceuticals provides a corporate update and reports financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) will present at three upcoming investor conferences in November. They will present at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology Conference on November 7th, the Piper Sandler 35th Annual Healthcare Conference on November 29th, and the Evercore ISI HealthCONx 6th Annual Conference on November 30th. Live webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals announces speakers for its Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals to host Investor & Analyst Event on DEE landscape and LP352 development for seizure treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
Longboard Pharmaceuticals, Inc.
Nasdaq:LBPH
LBPH Rankings
LBPH Stock Data
791.21M
25.54M
1.14%
63.94%
12.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
LA JOLLA
About LBPH
longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.